New treatment approach in Indian visceral leishmaniasis: Single-dose liposomal amphotericin b followed by short-course oral miltefosine

Clinical Infectious Diseases

Volumn 47, Issue 8, 2008, Pages 1000-1006

  Sundar, Shyam ^a,g   Rai, M ^a   Chakravarty, J ^a   Agarwal, D ^a   Agrawal, N ^b   Vaillant, Michel ^c   Olliaro, Piero ^d,e   Murray, Henry W ^f  

^a BANARAS HINDU UNIVERSITY   (India)

^b MLN MEDICAL COLLEGE   (India)

^c LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; AMPHOTERICIN B LIPID COMPLEX; CREATININE; MILTEFOSINE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD CELL COUNT; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIARRHEA; DRUG TOLERABILITY; HUMAN; INDIA; LABORATORY TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT INDICATION; TREATMENT RESPONSE; VISCERAL LEISHMANIASIS; VOMITING;

EID: 53349151814     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/591972     Document Type: Article

References (19)

1. Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 2000; 31:1104-7.
2. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366:1561-77.
3. Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 2005; 5:763-74.
4. Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002; 347:1739-46.
5. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007; 356:2571-81.
6. Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990; 84:221-5.
7. Thakur CP, Olliaro P, Gothoskar S, et al. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (p paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 1992; 86:615-6.
8. Seaman J, Pryce D, Sondorp HE, Moody A, Bryceson AD, Davidson RN. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plussodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 1993; 168:715-20.
9. Melaku Y, Collin SM, Keus K, Gatluak F, Ritmeijer K, Davidson RN. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg 2007; 77:89-94.
10. Guerin PJ, Olliaro P, Sundar S, et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002; 2:494-501.
11. Sundar S, Agrawal G, Rai M, Makharia MK, Murray HW. Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ 2001; 323:419-22.
12. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003; 37:800-4.
13. Sundar S, Makharia A, More DK, et al. Short-course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 2000; 31:1110-3.
14. Sundar S, Chakravarty J, Rai VK, et al. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis 2007; 45:556-61.
15. Sundar S, Jha TK, Thakur CP, Mishra M, Singh VR, Buffels R. Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: a multicenter study. Am J Trop Med Hyg 2002; 66:143-6.
16. Murray HW. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis. Expert Rev Anti Infect Ther 2004; 2:279-92.
17. Bhattacharya SK, Sinha PK, Sundar S, et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis 2007; 196:591-8.
18. Sundar S, Murray HW. Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 2005; 83:394-5.
19. Sundar S, Mehta H, Suresh AV, Singh SP, Rai M, Murray HW. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations. Clin Infect Dis 2004; 38:377-83.